tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robyn Karnauskas, 410 are a BUY (87.61%), 56 are a HOLD (11.97%), 2 are a SELL (0.43%).
Analyst Robyn Karnauskas, carries an average stock price target met ratio of 58% that have a potential upside of 47.98% achieved within 455 days. Previously, Robyn Karnauskas worked at TRUIST.
Robyn Karnauskas’s has documented 918 price targets and ratings displayed on 52 stocks. The coverage was on Healthcare, Technology, Energy sectors.
Most recent stock forecast was given on ABCL, Abcellera Biologics at 16-May-2025.
Analyst best performing recommendations are on FATE (FATE THERAPEUTICS).
The best stock recommendation documented was for FATE (FATE THERAPEUTICS) at 1/5/2023. The price target of $7 was fulfilled within 1 day with a profit of $4 (36.36%) receiving and performance score of 363.64.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 18-Nov-2020
$338
$46.69 (16.03%)
$282
8 days ago
(02-Nov-2026)
20/21 (95.24%)
$43.11 (14.62%)
335
Buy Since 05-Feb-2020
$322
$30.69 (10.54%)
$288
8 days ago
(02-Nov-2026)
45/46 (97.83%)
$27.11 (9.19%)
407
Buy Since 08-Dec-2021
$340
$48.69 (16.71%)
$300
8 days ago
(02-Nov-2026)
10/13 (76.92%)
$45.11 (15.30%)
514
Buy Since 02-Nov-2026
$342
$50.69 (17.40%)
$206
8 days ago
(02-Nov-2026)
19/20 (95%)
$47.11 (15.98%)
376
Buy Since 25-Feb-2026
$330
$38.69 (13.28%)
$280
8 days ago
(02-Nov-2026)
7/8 (87.5%)
$35.11 (11.91%)
173
